Arrowhead Pharmaceuticals, Inc. last reported quarterly results on Aug 4, 2026, for Q3 FY2026 (the quarter ended Jun 30, 2026): revenue of $75.3 million (+171.0% year over year) and diluted EPS of -$1.36. It usually reports 35–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 24, 2026.
Results for Q4 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 25, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Jun 30, 2026
|
75
+171.0%
|
-194
-10.9%
|
-1.36
-7.9%
|
|
May 7, 2026
37 days after quarter end
|
Q2 FY2026
ended Mar 31, 2026
|
74
-86.4%
|
-133
-135.8%
|
-0.93
-133.8%
|
|
Feb 5, 2026
36 days after quarter end
|
Q1 FY2026
ended Dec 31, 2025
|
264
+10461.3%
|
31
+117.8%
|
0.22
+115.8%
|
|
Nov 25, 2025
56 days after quarter end
|
Q4 FY2025
ended Sep 30, 2025
|
256
|
-24
+86.1%
|
-0.18
+87.2%
|
|
Aug 7, 2025
38 days after quarter end
|
Q3 FY2025
ended Jun 30, 2025
|
28
|
-175
-2.6%
|
-1.26
+8.7%
|
|
May 12, 2025
42 days after quarter end
|
Q2 FY2025
ended Mar 31, 2025
|
543
|
370
+395.6%
|
2.75
+369.6%
|
|
Feb 10, 2025
41 days after quarter end
|
Q1 FY2025
ended Dec 31, 2024
|
2
-29.6%
|
-173
-30.3%
|
-1.39
-12.1%
|
|
Nov 26, 2024
57 days after quarter end
|
Q4 FY2024
ended Sep 30, 2024
|
0
-100.0%
|
-171
-55.5%
|
-1.37
-34.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARWR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 879407
- Former names
- ARROWHEAD RESEARCH CORP (until Apr 6, 2016); INTERACTIVE GROUP INC (until Jan 9, 2004); INTERACTIVE INC (until Feb 13, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.